FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954080303> ?p ?o ?g. }

• W2954080303 endingPage "3680" @default.
• W2954080303 startingPage "3667" @default.
• W2954080303 abstract "// Sandeep Rajput 1 , Zhanfang Guo 1 , Shunqiang Li 1 , 2 and Cynthia X. Ma 1 , 2 1 Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA 2 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA Correspondence to: Cynthia X. Ma, email: cynthiaxma@wustl.edu Keywords: PI3K inhibitor; BKM120; eribulin; triple-negative breast cancer; patient-derived xenograft Received: March 18, 2019     Accepted: April 29, 2019     Published: June 04, 2019 ABSTRACT Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) is commonly observed in triple negative breast cancer (TNBC), leading to activation of the phosphoinositide 3-kinase (PI3K) signaling to promote tumor cell growth and chemotherapy resistance. In this study, we investigated whether adding a pan-PI3K inhibitor could improve the cytotoxic effect of eribulin, a non-taxane microtubule inhibitor, in TNBC patient-derived xenograft models (PDX) with loss of PTEN, and the underlying molecular mechanisms. Three TNBC-PDX models (WHIM6, WHIM12 and WHIM21), all with loss of PTEN expression, were tested for their response to BKM120 and eribulin, alone or in combination in vivo . In addition, the effect of drug treatment on cell proliferation and cell cycle progression were also performed in vitro using a panel of TNBC cell lines, including 2 derived from PDX models. The combination of eribulin and BKM120 led to additive or synergistic anti-tumor effect in 2 of the 3 PDX models, accompanied by an enhanced mitotic arrest and apoptosis in sensitive PDX models. In addition, the combination was synergistic in reducing mammosphere formation, and markers for epithelial-mesenchymal transition (EMT). In conclusion, PI3K inhibition induces synergistic anti-tumor effect when combined with eribulin, by enhancing mitotic arrest and apoptosis, as well as, reducing the cancer stem cell population. This study provides a preclinical rationale to investigate the therapeutic potential for the combination of PI3K inhibition and eribulin in the difficult to treat TNBC. Further studies are needed to identify the biomarkers of response for target patient selection." @default.
• W2954080303 created "2019-07-12" @default.
• W2954080303 creator A5009199118 @default.
• W2954080303 creator A5027185198 @default.
• W2954080303 creator A5034234418 @default.
• W2954080303 creator A5046254697 @default.
• W2954080303 date "2019-06-04" @default.
• W2954080303 modified "2023-09-24" @default.
• W2954080303 title "PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer" @default.
• W2954080303 cites W1599727238 @default.
• W2954080303 cites W1977267072 @default.
• W2954080303 cites W1983225377 @default.
• W2954080303 cites W2000969116 @default.
• W2954080303 cites W2003554910 @default.
• W2954080303 cites W2010098991 @default.
• W2954080303 cites W2018563247 @default.
• W2954080303 cites W2022292123 @default.
• W2954080303 cites W2028298372 @default.
• W2954080303 cites W2030764098 @default.
• W2954080303 cites W2044702943 @default.
• W2954080303 cites W2048071145 @default.
• W2954080303 cites W2050684389 @default.
• W2954080303 cites W2061860268 @default.
• W2954080303 cites W2062069198 @default.
• W2954080303 cites W2063382533 @default.
• W2954080303 cites W2065919583 @default.
• W2954080303 cites W2067254500 @default.
• W2954080303 cites W2072544833 @default.
• W2954080303 cites W2073308507 @default.
• W2954080303 cites W2096027508 @default.
• W2954080303 cites W2096283457 @default.
• W2954080303 cites W2099919029 @default.
• W2954080303 cites W2111223585 @default.
• W2954080303 cites W2116355318 @default.
• W2954080303 cites W2118605519 @default.
• W2954080303 cites W2123664371 @default.
• W2954080303 cites W2124924712 @default.
• W2954080303 cites W2125094267 @default.
• W2954080303 cites W2127152525 @default.
• W2954080303 cites W2130363647 @default.
• W2954080303 cites W2134539328 @default.
• W2954080303 cites W2135721953 @default.
• W2954080303 cites W2137586381 @default.
• W2954080303 cites W2138941973 @default.
• W2954080303 cites W2139248766 @default.
• W2954080303 cites W2142577868 @default.
• W2954080303 cites W2145260509 @default.
• W2954080303 cites W2152654745 @default.
• W2954080303 cites W2157285286 @default.
• W2954080303 cites W2159750196 @default.
• W2954080303 cites W2159890963 @default.
• W2954080303 cites W2169105660 @default.
• W2954080303 cites W2170602872 @default.
• W2954080303 cites W2217019432 @default.
• W2954080303 cites W2338265146 @default.
• W2954080303 cites W2388163742 @default.
• W2954080303 cites W2430731787 @default.
• W2954080303 cites W2560367415 @default.
• W2954080303 cites W2604732382 @default.
• W2954080303 cites W2743639018 @default.
• W2954080303 cites W2748521059 @default.
• W2954080303 cites W2789273393 @default.
• W2954080303 cites W2800852522 @default.
• W2954080303 cites W2805333318 @default.
• W2954080303 cites W320478385 @default.
• W2954080303 cites W4243840835 @default.
• W2954080303 doi "https://doi.org/10.18632/oncotarget.26960" @default.
• W2954080303 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6557212" @default.
• W2954080303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31217901" @default.
• W2954080303 hasPublicationYear "2019" @default.
• W2954080303 type Work @default.
• W2954080303 sameAs 2954080303 @default.
• W2954080303 citedByCount "6" @default.
• W2954080303 countsByYear W29540803032020 @default.
• W2954080303 countsByYear W29540803032021 @default.
• W2954080303 countsByYear W29540803032022 @default.
• W2954080303 countsByYear W29540803032023 @default.
• W2954080303 crossrefType "journal-article" @default.
• W2954080303 hasAuthorship W2954080303A5009199118 @default.
• W2954080303 hasAuthorship W2954080303A5027185198 @default.
• W2954080303 hasAuthorship W2954080303A5034234418 @default.
• W2954080303 hasAuthorship W2954080303A5046254697 @default.
• W2954080303 hasBestOaLocation W29540803031 @default.
• W2954080303 hasConcept C121608353 @default.
• W2954080303 hasConcept C126322002 @default.
• W2954080303 hasConcept C143998085 @default.
• W2954080303 hasConcept C185592680 @default.
• W2954080303 hasConcept C190283241 @default.
• W2954080303 hasConcept C2775930923 @default.
• W2954080303 hasConcept C2776387010 @default.
• W2954080303 hasConcept C2777511904 @default.
• W2954080303 hasConcept C2777609662 @default.
• W2954080303 hasConcept C2779549131 @default.
• W2954080303 hasConcept C2780110267 @default.
• W2954080303 hasConcept C502942594 @default.
• W2954080303 hasConcept C530470458 @default.
• W2954080303 hasConcept C55493867 @default.
• W2954080303 hasConcept C71924100 @default.

• next